KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Short term Debt (2017 - 2025)

BeOne Medicines (ONC) has disclosed Short term Debt for 10 consecutive years, with $57.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt fell 93.27% to $57.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.3 million, a 93.27% decrease, with the full-year FY2025 number at $57.3 million, down 93.27% from a year prior.
  • Short term Debt was $57.3 million for Q4 2025 at BeOne Medicines, up from $52.2 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $863.8 million in Q3 2024 to a low of $52.2 million in Q3 2025.
  • A 5-year average of $479.5 million and a median of $427.6 million in 2021 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: skyrocketed 193.45% in 2024, then tumbled 93.95% in 2025.
  • BeOne Medicines' Short term Debt stood at $427.6 million in 2021, then crashed by 64.92% to $150.0 million in 2022, then surged by 119.04% to $328.6 million in 2023, then surged by 159.17% to $851.5 million in 2024, then plummeted by 93.27% to $57.3 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Short term Debt are $57.3 million (Q4 2025), $52.2 million (Q3 2025), and $808.4 million (Q2 2025).